Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 single-arm trial of oregovomab + bevacizumab + paclitaxel + carboplatin in BRCA-wild type platinum-sensitive recurrent ovarian/tubal/primary peritoneal cancer
KCT0005461Phase 2Not yet recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab, bevacizumab, paclitaxel, carboplatin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Ministry of Health & Welfare. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
oregovomabbevacizumabpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0005461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005461.